According to the company, the agreement would resolve nearly all remaining talc-related ovarian cancer claims against J&J. The deal still requires approval from 95% of ovarian cancer claimants in state and federal courts before it becomes final. Chris Seeger, an attorney representing about 2,500 plaintiffs who helped negotiate the agreement, said the settlement assigns specific values to qualifying ovarian cancer claims but does not cap J&J’s total financial obligation. Johnson & Johnson stopped selling talc-based baby powder in the United States in 2020, replacing it with a cornstarch-based product. Before those bankruptcy attempts, Johnson & Johnson experienced mixed outcomes in court, including a multibillion-dollar verdict awarded to 22 women who alleged the company’s baby powder caused their ovarian cancer.